Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. Issue 5 (10th May 2021)

• Record Type: Journal Article
• Authors: Inoue, Kosuke; Figueroa, Jose F.; DeJong, Colette; Tsugawa, Yusuke; Orav, E. John; Shen, Changyu; Kazi, Dhruv S.
• Is Part Of: Circulation. Volume 14:Issue 5(2021)
• Page Start: e007521
• Publication Date: 2021-05-10
• Subjects: marketing -- Medicare -- prescription -- prior authorization -- United States; Cardiovascular system -- Diseases -- Treatment -- Periodicals; Cardiovascular system -- Diseases -- Research -- Periodicals; Outcome assessment (Medical care) -- Periodicals; Evidence-based medicine -- Periodicals; 616.1007
• DOI: 10.1161/CIRCOUTCOMES.120.007521
• Languages: English
• ISSNs: 1941-7713

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : Background: Marketing payments from the pharmaceutical industry to physicians have come under scrutiny due to their potential to influence clinical decision-making. Two proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) were approved by the US Food and Drug Administration in 2015 for reducing low-density lipoprotein cholesterol in high-risk patients, but their initial uptake was limited due to their high-cost and stringent prior authorization requirements. We sought to investigate the association between industry marketing and early adoption of PCSK9i among US physicians. Methods: We used nationwide databases of primary care physicians, cardiologists, and endocrinologists treating Medicare beneficiaries to examine the association between PCSK9i-related marketing payments in 2016 and the number of filled PCSK9i prescriptions in 2017, after adjusting for physician characteristics. In subgroup analyses, we stratified our analyses by physician specialty and prior experience with prescribing PCSK9i. Results: Among 209 840 physicians included in this analysis, 49 341 (24%) physicians received 292 941 PCSK9i-related marketing payments in 2016. The total value of these payments was $19 million, with a median payment of $61 per physician (interquartile range, $25–$132). Most payments (95%) were for meals, with a median of $14 per meal. The receipt of PCSK9i-related payments in 2016 was associated with increased PCSK9i prescription in 2017 (adjusted risk ratio, 3.18 [95% CI, 2.95–3.42]). This association was larger among primary care physicians (adjusted risk ratio, 6.67 [95% CI, 5.87–7.57]) than cardiologists (adjusted risk ratio, 2.00 [95% CI, 1.84–2.16]) and endocrinologists (adjusted risk ratio, 4.06 [95% CI, 2.95–5.59]). The association was observed across all types of payments. Conclusions: At a time when few physicians had experience with prescribing PCSK9i under strict prior authorization requirements, industry marketing payments to physicians for PCSK9i, predominantly in the form of meals, were associated with increased PCSK9i prescription in the subsequent year.